Multicenter Uveitis Steroid Treatment (MUST) Trial

JHSPH Center for Clinical Trials

Status and phase

Completed

Phase 4

Conditions

Uveitis

Treatments

Drug: fluocinolone acetonide intraocular implant

Drug: oral corticosteroid with immunosuppressive agents as needed

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00132691

1U10EY014660-2

NEI-106

U10EY014660 (U.S. NIH Grant/Contract)

ISRCTN15396562

Details and patient eligibility

About

The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

Full description

The MUST trial is a randomized controlled clinical trial comparing two treatments for patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or panuveitis:

local therapy with fluocinolone acetonide intraocular implant in affected eyes; versus
standard therapy: systemic corticosteroid therapy supplemented, when indicated, by corticosteroid-sparing potent immuno-modulator therapy.

Study ophthalmologists, clinic coordinators, and patients will not be masked to treatment assignment. Masking will be applied to the determination of visual function at baseline, the six month visit, and thereafter . Patients will be followed until death, participant withdrawal, or a common study closeout. Patients will be seen at baseline, one month after randomization, three months after randomization, and every three months thereafter for data collection. Both ophthalmological and medical data will be collected to evaluate the outcomes of treatment of the uveitis, complications of the uveitis, and complications from therapy itself. Selected laboratory data related to the complications from systemic corticosteroid therapy will be collected.

The planned sample size of 250 patients, 125 per treatment group, is expected to give sufficient power to detect clinically important differences in visual acuity outcomes. Patients meeting the eligibility criteria detailed above will be enrolled at approximately 23 clinical centers in the United States, Australia and UK. Patients will be randomized on a 1:1 basis to one of the two treatment groups.

The MUST Research Group received additional funding at the completion of the MUST Trial to continue following patients enrolled in the study for an additional 7 years in the MUST Trial Follow-up Study (MUST FS). Since uveitis is often a chronic condition requiring long-term treatment, the objectives of the MUST FS are to evaluate outcomes of the two treatments over a longer period time. The outcomes specified for MUST FS are the same as those specified for the MUST Trial: visual acuity, ocular and systemic side effects of treatment, quality of life, and control of ocular inflammation. The primary analyses will be to compare outcomes between the original randomization groups, i.e., intention-to-treat. Secondary analyses will be based on treatment received. Study visits will be conducted every 6 months in MUST FS as opposed to every 3 months in the MUST Trial. Two analyses are planned for public release, one at 4.5 years and one after 7 years of follow-up. The Data Safety Monitoring Board reviewed and approved the analysis plan.

Enrollment

255 patients

Sex

All

Ages

13+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 13 years or older
Best-corrected visual acuity of hand motions or better in at least one eye with uveitis
Intraocular pressure 24 mm Hg or less in all eyes with uveitis

Exclusion criteria

Inadequately controlled diabetes
Uncontrolled glaucoma
Advanced glaucomatous optic nerve injury
A history of scleritis; presence of an ocular toxoplasmosis scar.
HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated according to best medical judgment